AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production
Tomohiro Fujii(Suzuki (Japan)), Kei Yamada(Kurume University), Tatsuya Okuzumi(Suzuki (Japan)), Natsuki Shikida(Suzuki (Japan)), Sayaka Kawaguchi(Suzuki (Japan)), Akira Nakayama(Shizuoka University), Yutaka Matsuda(Ajinomoto (United States)), Muneki Isokawa(Suzuki (Japan)), Tomohiro Watanabe(Ajinomoto (United States)), Brian A. Mendelsohn(Seagen (United States)), Noriko Hatada(Suzuki (Japan)), Takuya Seki(Suzuki (Japan)), Kazutoshi Takahashi(Suzuki (Japan)), Yuri Ooba(Suzuki (Japan)), Kazutaka Shimbo(Suzuki (Japan)), Rika Takasugi(Suzuki (Japan)), Yusuke Iwai(Suzuki (Japan))
Cited by 62
Related Papers
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
|Bioconjugate Chemistry|2005|511
Inhibitor hijacking of Akt activation
|Nature Chemical Biology|2009|296